Physician profile
Meeta Bhalla
NPI 1558776765
$850.27
in general payments reported to CMS, 2019-2025
9 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $226 · 2024: $234 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.24 |
| Education | $213.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $261.13 | 2024-2025 | Rezdiffra |
| W. L. Gore & Associates, INC. | $233.01 | 2023-2024 | Seamguard, Gore Enform Preperitoneal Biomaterial |
| Esteve Pharmaceuticals LLC | $155.73 | 2025 | Metopirone |
| Medtronic, INC. | $82.30 | 2023 | Ligasure |
| Xeris Pharmaceuticals, INC. | $43.42 | 2025 | Recorlev |
| Ascendis Pharma Endocrinology INC | $24.05 | 2025 | Yorvipath |
| Amgen INC. | $17.79 | 2025 | Prolia, Evenity |
| Rhythm Pharmaceuticals, INC. | $17.50 | 2025 | Imcivree |
| Sanofi-Aventis U.S. LLC | $15.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meeta Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.